by Nataliya Melnyk, and Jonathan Harrison

Slides:

Advertisements

Similar presentations

MGUS (interpreting the test you didnt order) Family Medicine Review Course 2011 Christian Cable, MD, FACP.

Advertisements

RNA interference in biology and disease by Carol A. Sledz, and Bryan R. G. Williams Blood Volume 106(3): August 1, 2005 ©2005 by American Society.

Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival by Sandra L. Haberichter,

IMMUNOCHEMISTRY PROFILES Dr. Thomas Williams. TESTS DISEASES CASES.

Multiple Myeloma Definition:

Inherited bleeding disorder of primary hemostasis.

Von Willebrand’s Disease (vWD) Among women with unexplained menorrhagia.

INHERITED DISORDERS OF COAGULATION von Willebrand Disease 1.

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

Nursing Management: Hematologic Problems Chapter 31 Overview Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc.

Pathogenesis beyond the cancer clone(s) in multiple myeloma by Giada Bianchi, and Nikhil C. Munshi Blood Volume 125(20): May 14, 2015 ©2015 by.

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Increased Clearance Explains the Ultra-Large Multimers in Von Willebrand Disease Type 2M Vicenza; Lessons from Recombinant VWF Vicenza and Modeling of.

M protein detection and characterization

MLAB Hematology Keri Brophy-Martinez

Pattern of inheritance and laboratory findings in von Willebrand disease (VWD). The assays of platelet function include a coagulation assay of factor VIII.

MLAB Hematology Fall 2007 Keri Brophy-Martinez

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study by Pier M. Mannucci,

MBL: mostly benign lymphocytes, but…

Elevated Serum Levels Of Von Willebrand Factor (vWF) Predict For Early Death and Shorter Survival In Patients With Primary Systemic Light Chain (AL) Amyloidosis.

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

Section III Physiological Biochemistry Universities Press

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.

Enlightening light chain deposition disease

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

Successful Aortic Valve Replacement for Heyde Syndrome With Confirmed Hematologic Recovery Atsutomo Morishima, MD, Akira Marui, MD, PhD, Takeshi Shimamoto,

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Critiquing Cryos by Morie Gertz Blood Volume 111(11):

A young patient with multiple myeloma

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Darwinian evolution and tiding clones in multiple myeloma

The role of complete response in multiple myeloma

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Genetic sequence analysis of inherited bleeding diseases

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.

Parasternal mass Blood Volume 113(6): February 5, 2009

Thrombin generation: biochemical possibilities and clinical reality

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

by Ernest Beutler Blood Volume 98(9): November 1, 2001

by Nelson Leung, Samih H. Nasr, and Sanjeev Sethi

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular.

Total-Thrombus-Formation Analysis System Using a Microchip Flow Chamber Reflects Bleeding Severity of Patients with Type 1 Von Willebrand Disease. by Kenichi.

Molecular Mechanism of a Mild Phenotype in Coagulation Factor XIII (FXIII) Deficiency: A Splicing Mutation Permitting Partial Correct Splicing of FXIII.

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.

HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8–positive plasmablastic lymphoma by Nicolas Dupin, Tim L.

Characterization of W1745C and S1783A: 2 novel mutations causing defective collagen binding in the A3 domain of von Willebrand factor by Anne F. Riddell,

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: Mechanical demolition and enzymatic.

Acquired type 2A von Willebrand syndrome caused by aortic valve disease corrects during valve surgery C. Solomon, U. Budde, S. Schneppenheim, E. Czaja,

Acquired and Reversible von Willebrand Disease With High Shear Stress Aortic Valve Stenosis Kazunori Yoshida, MD, Satoshi Tobe, MD, Masahito Kawata,

High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin.

Kazunori Yoshida, MD, Satoshi Tobe, MD, Masahito Kawata, MD

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Significant gynecological bleeding in women with low von Willebrand factor levels by Michelle Lavin, Sonia Aguila, Niall Dalton, Margaret Nolan, Mary Byrne,

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

by Giovanni Palladini, and Giampaolo Merlini

by Wendy Lim, Sara K. Vesely, and James N. George

Pure red cell aplasia by Robert T. Means Blood

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Cold agglutinin disease

Karanprit Singh, Prateek Chapalamadugu, Peter Malet

Presentation transcript:

by Nataliya Melnyk, and Jonathan Harrison Concomittant Acquired Von Willebrand Disease and Acquired Factor V Deficiency Causing a Severe Bleeding Diathesis Due To Multiple Myeloma With Amyloidosis by Nataliya Melnyk, and Jonathan Harrison Blood Volume 122(21):4788-4788 November 15, 2013 ©2013 by American Society of Hematology

Normal von Willebrand protein multimers (top) by gel electrophersis, and patient's multimers by gel electrophoresis (bottom), consistent with Type II vWD. Normal von Willebrand protein multimers (top) by gel electrophersis, and patient's multimers by gel electrophoresis (bottom), consistent with Type II vWD. Jonathan Harrison Blood 2013;122:4788 ©2013 by American Society of Hematology

Spectroscopic Analysis of the proteins extracted from the patient's lymph node, showing the presence of immunoglobulin lambda light chain (numbers 8 and 11). Spectroscopic Analysis of the proteins extracted from the patient's lymph node, showing the presence of immunoglobulin lambda light chain (numbers 8 and 11). Jonathan Harrison Blood 2013;122:4788 ©2013 by American Society of Hematology